Intended Use: Tesamorelin is designed for Research Purposes only.

Storage: Store the vial in a cool, dry place away from direct sunlight. Once reconstituted, keep refrigerated at 2-8°C.

Solubility: Reconstitute with bacteriostatic water for best results.

Shelf Life: The lyophilized form has a shelf life of 24 months when properly stored. Once reconstituted, refrigerate and use within 4-6 weeks.

Handling: Ensure sterile techniques are used to maintain the product’s integrity during research.

Impact of Tesamorelin on Visceral Fat on Patients with Lipodystrophy

Objective: This clinical trial aimed to evaluate tesamorelin’s efficacy in reducing visceral adipose tissue in patients with lipodystrophy, a condition characterized by abnormal fat distribution.

Method: Researchers conducted a randomized, double-blind, placebo-controlled trial with over 400 participants who received tesamorelin injections for 26 weeks.

Findings: Patients treated with tesamorelin experienced a significant reduction in visceral fat compared to the placebo group, with improvements in waist circumference and body composition. The study demonstrated that tesamorelin effectively reduced abdominal fat with few side effects, affirming its value in managing HIV-associated lipodystrophy.

Tesamorelin and Cognitive Function: Exploring Growth Hormone Pathways in Older Adults

Objective: This study investigated the potential cognitive benefits of tesamorelin in older adults, based on the hypothesis that growth hormone pathways may support cognitive health.

Method: Conducted on a smaller group of aging participants, the study assessed cognitive function using standardized tests before and after a 6-month tesamorelin treatment period.

Findings: Researchers observed moderate improvements in memory and executive function among participants, suggesting that tesamorelin may have positive effects on brain health. While preliminary, these findings point to a new avenue for tesamorelin research in age-related cognitive decline.

Effects of Tesamorelin on Cardiovascular Risk Markers in Abdominal Obesity

Objective: This study focused on the impact of tesamorelin on cardiovascular risk markers, given its ability to reduce visceral fat linked to metabolic issues.

Method: In a placebo-controlled trial with individuals with high abdominal fat, tesamorelin was administered for 12 months, with researchers monitoring changes in lipid profiles, blood pressure, and inflammatory markers.

Findings: Participants showed reduced triglyceride levels and improved cholesterol ratios, suggesting potential benefits for cardiovascular health. These results support tesamorelin’s promise as a therapeutic option for patients with high cardiovascular risk due to central obesity.

Tesamorelin mimics growth hormone-releasing hormone (GHRH), stimulating the pituitary gland to increase natural growth hormone production. This boost in growth hormone promotes fat metabolism, particularly targeting visceral fat, while aiding muscle preservation. Its action on metabolic pathways also supports improved lipid profiles and insulin sensitivity.